NR1H4 and metabolic dysfunction-associated steatohepatitis: Preclinical studies and clinical trials have been processed to evaluate potential treatment options for NAFLD and NASH, including synbiotics, pan-caspase inhibitors, CCR2/5 antagonists, FXR agonists, and so on.